文献速递艾滋病与性传播感染结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

奈韦拉平与利福喷丁/异烟肼联用时的药代动力学

Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

该研究基于BRIEF-TB研究,纳入接受奈韦拉平的HIV感染者,评估每日利福喷丁联合异烟肼预防结核4周期间的药物相互作用。结果显示,联用期间奈韦拉平表观口服清除率显著升高,GMR(90%CI)为1.30(1.26-1.33),提示利福喷丁/异烟肼不应与含奈韦拉平的抗逆转录病毒治疗(ART)每日联用。

要点

  • 联用利福喷丁/异烟肼期间奈韦拉平清除率显著升高。
  • 多数受试者第2、4周谷浓度仍≥3000 ng/mL。
  • 不建议每日利福喷丁/异烟肼与含奈韦拉平ART联用。

核心结论

  • 奈韦拉平CL/F在联用利福喷丁/异烟肼期间显著升高,提示诱导奈韦拉平代谢。

研究设计与样本

  • BRIEF-TB研究中接受奈韦拉平并随机进入利福喷丁/异烟肼组的HIV感染者,共78例有可评估PK数据。

主要发现

  • 奈韦拉平谷浓度中位数(IQR):第0周7322(5266-9302)ng/mL,第2周5537(3552-8462)ng/mL,第4周5388(3516-8243)ng/mL。
  • CL/F中位数(IQR):联用前2.03(1.58-2.58)L/h,联用期间2.62(1.81-3.42)L/h;GMR(90%CI)为1.30(1.26-1.33)。

关键数值与推荐

  • CL/F的GMR(90%CI)为1.30(1.26-1.33)。
  • 77%参与者在第2、4周谷浓度均≥3000 ng/mL。

临床怎么用

  • 每日利福喷丁/异烟肼用于结核预防时,不应与含奈韦拉平的ART联合给药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The use of rifamycin antibiotics for TB prevention carries a risk of detrimental drug-drug interactions with concomitantly used ART. OBJECTIVES: To evaluate the interaction of the antiretroviral drug nevirapine in combination with 4 weeks of daily rifapentine and isoniazid for TB prevention in people living with HIV. METHODS: Participants were individuals enrolled in the BRIEF-TB study receiving nevirapine and randomized to the rifapentine/isoniazid arm of the study. Participants provided sparse pharmacokinetic (PK) sampling at baseline and weeks 2 and 4 for trough nevirapine determination. Nevirapine apparent oral clearance (CL/F) was estimated and the geometric mean ratio (GMR) of CL/F prior to and during rifapentine/isoniazid was calculated. RESULTS: Seventy-eight participants had evaluable PK data: 61 (78%) female, 51 (65%) black non-Hispanic and median (range) age of 40 (13-66) years. Median (IQR) nevirapine trough concentrations were: week 0, 7322 (5266-9302) ng/mL; week 2, 5537 (3552-8462) ng/mL; and week 4, 5388 (3516-8243) ng/mL. Sixty out of 78 participants (77%) had nevirapine concentrations ≥3000 ng/mL at both week 2 and 4. Median (IQR) nevirapine CL/F values were: week 0 pre-rifapentine/isoniazid, 2.03 (1.58-2.58) L/h; and during rifapentine/isoniazid, 2.62 (1.81-3.42) L/h. The GMR (90% CI) for nevirapine CL/F was 1.30 (1.26-1.33). CONCLUSIONS: The CL/F of nevirapine significantly increased with concomitant rifapentine/isoniazid. The decrease in nevirapine trough concentrations during rifapentine/isoniazid therapy suggests induction of nevirapine metabolism, consistent with known rifapentine effects. The magnitude of this drug-drug interaction suggests daily rifapentine/isoniazid for TB prevention should not be co-administered with nevirapine-containing ART.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Podany AT, Leon-Cruz J, Hakim J, et al. Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention. J Antimicrob Chemother. 2021. PMID: 33241266. doi:10.1093/jac/dkaa470

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。